Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study. Issue 7 (August 2015)

• Record Type: Journal Article
• Authors: Oriol, Albert; Giraldo, Pilar; Kotsianidis, Ioannis; Couturier, Catherine; Olie, Robert; Angermund, Ralf; Corso, Alessandro
• Is Part Of: Hematology. Volume 20:Issue 7(2015)
• Page Start: 405
• Page End: 409
• Publication Date: 2015-08
• Subjects: Multiple myeloma -- Retreatment -- Bortezomib -- Efficacy -- Safety; Blood -- Diseases -- Periodicals; Hematology -- Periodicals; Blood -- Transfusion -- Periodicals; 616.15005
• DOI: 10.1179/1607845414Y.0000000218
• Languages: English
• ISSNs: 1024-5332

Abstract

Abstract : Objective: Multiple myeloma remains incurable and retreatment with available therapies is of substantial interest. Methods: This retrospective observational study included data from 35 patients treated initially and at the first relapse with bortezomib-containing regimens. Results: Bortezomib retreatment provided a similar depth and time to response as first-line therapy; however, as could be expected, the duration of response was shorter with retreatment. The tolerability profile was similar with bortezomib as the first- and second-line therapy, with no evidence of cumulative toxicity. Conclusion: These findings support bortezomib retreatment after a treatment-free interval of ≥6 months in patients who achieved at least a partial response to the first-line bortezomib-based therapy.